Capricor Therapeutics (CAPR) Q4 2024 earnings summary

Executive summary

• BLA for deramyocel in DMD cardiomyopathy accepted by FDA for priority review, with PDUFA date set for August 31, 2025.

• Deramyocel demonstrated statistically and clinically significant efficacy, including 52% slowing of disease progression over 3 years in HOPE-2 OLE, and a strong safety profile.

• Commercial launch preparations underway with NS Pharma/Nippon Shinyaku, leveraging established Duchenne infrastructure.

• Manufacturing capacity being expanded, with new facility expected online by mid-2026 and additional 25,000 sq ft leased.

• Ended 2024 with $151.5M in cash, received $10M milestone, and operations funded into 2027.

Financial highlights

• Q4 2024 revenue was $11.1M, down from $12.1M in Q4 2023; full-year 2024 revenue was $22.3M, down from $25.2M in 2023.

• Q4 2024 net loss was $7.1M ($0.16/share), compared to $0.8M ($0.02/share) in Q4 2023; full-year 2024 net loss was $40.5M ($1.15/share), up from $22.3M ($0.83/share) in 2023.

• R&D expenses increased to $13.6M in Q4 2024 from $9.4M in Q4 2023; G&A expenses rose to $3M from $2.1M.

• Operating expenses rose to $18.8M in Q4 2024 (from $13.4M) and $64.8M for 2024 (from $49.3M).

• Completed $80.8M public offering in October 2024.

Outlook and guidance

• Anticipates FDA approval decision by August 31, 2025, with potential $80M milestone and priority review voucher upon approval.

• Manufacturing expansion to support up to 3,000 patients per year by mid-2026; initial facility can support 250-500 patients annually.

• Commercial launch expected Q4 2025, with 100 patients transferring from open-label extension trial.

• Cash runway extends into 2027 without additional financing.

• Preparing for potential commercial launch of deramyocel with Nippon Shinyaku, pending FDA approval.